Consumo e digestibilidade de feno de baixa qualidade suplementado com nitrogênio não protéico em bovinos Intake and digestibility of low-quality hay with nonprotein nitrogen supplementation in cattle

O objetivo deste trabalho foi avaliar o efeito de níveis de inclusão de nitrogênio não protéico, em suplementos fornecidos a tourinhos Hereford, com 17 meses e peso médio de 220 kg, alimentados com feno de tifton (Cynodon dactylon) ad libitum. Os tratamentos avaliados foram: feno + suplemento sem uréia; feno + suplemento com 0,28 g de uréia kg-1 PV0,75; feno + suplemento com 0,55 g de uréia kg-1 PV0,75; feno + suplemento com 0,83 g de uréia kg-1 PV0,75 e feno + suplemento com 1,11 g de uréia kg-1 PV0,75. O feno apresentou, na média, 3,86% de proteína bruta e 84,66% de fibra em detergente neutro. Não se constatou efeito da suplementação sobre a digestibilidade da matéria orgânica, matéria orgânica do feno, fibra em detergente neutro, celulose e hemicelulose; o consumo total desses itens respondeu quadraticamente à suplementação com níveis crescentes de nitrogênio não protéico. A suplementação não afetou a excreção fecal metabólica de matéria orgânica, o que sugere aumento na taxa de passagem (variação no consumo) e na taxa de digestão (digestibilidade constante). O consumo de matéria orgânica digestível apresentou comportamento quadrático com aumento dos níveis de uréia na dieta. Quando o nível de proteína degradável no rúmen foi equivalente a 8,1% da matéria orgânica digestível, a relação de consumo entre esses componentes foi otimizada.<br>The objective of this work was to evaluate the effect of nonprotein nitrogen supplementation levels on the digestibility of low-quality hay (Cynodon dactylon), which was offered ad libitum to Hereford bulls aging 17 months and weighing 220 kg. The evaluated treatments were: hay + no urea supplement; hay + supplement with 0.28 g urea kg- 1 BW0.75; hay + supplement with 0.55 g urea kg-1 BW0.75; hay + supplement with 0.83 g urea kg- 1 BW0.75 and hay + supplement with 1.11 g urea kg- 1 BW0.75. Hay composition presented 3.86% of crude protein and 84.66% of neutral detergent fiber. Digestibility of organic matter, organic matter of forage, neutral detergent fiber, cellulose and hemicellulose were not affected by nonprotein nitrogen level; total intake of these components showed a quadratic response to nonprotein nitrogen supplementation. Organic matter metabolic fecal excretion was not affected by supplementation, suggesting a simultaneous increase in both passage (intake increase) and digestion rates (stable digestibility). The digestible organic matter intake showed a quadratic response with the increase of urea supplementation levels. The relationship between rumen degradable protein intake and digestible organic matter intake showed a maximization point, when rumen degradable protein intake was equivalent to 8.1% of digestible organic matter intake

Antiinflammatory therapy with canakinumab for atherosclerotic disease

BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. METHODS: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P=0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P=0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P=0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P=0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P=0.31). CONCLUSIONS: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. Copyright © 2017 Massachusetts Medical Society